The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder

Open Access

Peer-reviewed

Research Article

About the Authors

Shinji Takahashi

Roles Investigation, Writing – original draft

Affiliation Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan

Makoto Ohmiya

Roles Investigation, Writing – review & editing

Affiliation Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan

Sokichi Honda

Roles Investigation, Writing – review & editing

Affiliation Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan

Keni Ni

Roles Supervision

Affiliation Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan

All Authors are employees of Astellas Pharma Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

ADHD
Is the Subject Area "ADHD" applicable to this article?

Thanks for your feedback.
Attention
Is the Subject Area "Attention" applicable to this article?

Thanks for your feedback.
Impulsivity
Is the Subject Area "Impulsivity" applicable to this article?

Thanks for your feedback.
Amphetamines
Is the Subject Area "Amphetamines" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Electroencephalography
Is the Subject Area "Electroencephalography" applicable to this article?

Thanks for your feedback.
Potassium channels
Is the Subject Area "Potassium channels" applicable to this article?

Thanks for your feedback.